Back to Search Start Over

Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry

Authors :
Margaret F. Meagher
Maria C Mir
Riccardo Autorino
Andrea Minervini
Maximilian Kriegmair
Tobias Maurer
Francesco Porpiglia
Siska Van Bruwaene
Estefania Linares
Vital Hevia
Mireia Musquera
Eduard Roussel
Nicola Pavan
Alessandro Antonelli
Shudong Zhang
Fady Ghali
Devin Patel
Juan Javier-Desloges
Aaron Bradshaw
Jose Rubio
Georgi Guruli
Andrew Tracey
Riccardo Campi
Maarten Albersen
Maria Furlan
Rana R. McKay
Ithaar H. Derweesh
Source :
Clinical Genitourinary Cancer. 20:326-333
Publication Year :
2022
Publisher :
Elsevier BV, 2022.

Abstract

Treatment paradigms for management of metastatic renal cell carcinoma (mRCC) are evolving. We examined impact of surgical metastasectomy on survival across in mRCC stratified by risk-group.Multicenter retrospective analysis from the Registry of Metastatic RCC database. The cohort was subdivided utilizing Motzer criteria (favorable-, intermediate-, high-risk). Primary outcome was all-cause mortality (ACM)/overall survival (OS); secondary outcome was cancer-specific mortality (CSM)/cancer-specific survival (CSS). Impact of metastasectomy was analyzed via Cox-Regression analysis adjusting for potential prognostic variables and Kaplan-Meier analysis (KMA) within each risk-group.Four hundred thirty-one patients (59 favorable-risk, 274 intermediate-risk, 98 high-risk; median follow-up 27.2 months) were analyzed. Metastasectomy was performed in 22 (37%), 66 (24%), and 32 (16%) of favorable-, intermediate- and high-risk groups (P = .012). Median number of metastases at diagnosis differed significantly (favorable-risk 2, intermediate-risk 3.4, high-risk 5.1, P.001). On Cox-regression, high-risk (HR = 1.72, P = .002) was associated with worsened ACM, while metastasectomy was associated with improved ACM (HR = 0.56, P = .005). On KMA, median OS (months) was longer with metastasectomy in favorable- (92.7 vs. 25.8, P = .003) and intermediate-risk (26.3 vs. 20.1, P = .038), but not high-risk (P = .911) groups. Metastasectomy was associated with longer CSS in favorable- (76.1 vs. 32.8, P = .004) but not intermediate- (P = .06) and high-risk (P = .595) groups.Metastasectomy was independently associated with improved ACM and CSM, as well as improved CSS and OS in favorable- and intermediate-risk mRCC patients. Metastasectomy may be considered as component of multimodal management strategy in favorable and intermediate-risk subgroups. In high-risk patients, metastasectomy should be deferred except in select circumstances.

Details

ISSN :
15587673
Volume :
20
Database :
OpenAIRE
Journal :
Clinical Genitourinary Cancer
Accession number :
edsair.doi.dedup.....7dbb707e49531a1d2dbaf5ed3135fcdb
Full Text :
https://doi.org/10.1016/j.clgc.2022.03.013